A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors  by Annenkov, Alexander et al.
Biochimica et Biophysica Acta 1813 (2011) 1428–1437
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrA chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a
single chain antibody speciﬁc to myelin oligodendrocyte glycoprotein activates the
IGF1R signalling cascade in CG4 oligodendrocyte progenitors
Alexander Annenkov a, Anne Rigby a, Sandra Amor b, Dun Zhou c, Nasim Yousaf a,
Bernhard Hemmer c, Yuti Chernajovsky a,⁎
a Bone and Joint Research Unit, William Harvey Research Institute, Bart's and the London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
b Department of Pathology, VU Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
c Department of Neurology, Heinrich Heine University, 40225 Dusseldorf, Germany⁎ Corresponding author. Tel.: +44 207 882 6122; fax
E-mail address: y.chernajovsky@qmul.ac.uk (Y. Cher
0167-4889/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbamcr.2011.04.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 5 November 2010
Received in revised form 24 April 2011
Accepted 25 April 2011
Available online 4 May 2011
Keywords:
Receptor tyrosine kinase
Insulin-like growth factor receptor type I
Regenerative medicine
Gene therapy
Oligodendrocyte progenitor
Chimeric receptorIn order to generate neural stem cells with increased ability to survive after transplantation in brain
parenchyma we developed a chimeric receptor (ChR) that binds to myelin oligodendrocyte glycoprotein
(MOG) via its ectodomain and activates the insulin-like growth factor receptor type 1 (IGF1R) signalling
cascade. Activation of this pro-survival pathway in response to ligand broadly available in the brain might
increase neuroregenerative potential of transplanted precursors. The ChR was produced by fusing a MOG-
speciﬁc single chain antibody with the extracellular boundary of the IGF1R transmembrane segment. The ChR
is expressed on the cellular surface, predominantly as a monomer, and is not N-glycosylated. To show MOG-
dependent functionality of the ChR, neuroblastoma cells B104 expressing this ChR were stimulated with
monolayers of cells expressing recombinant MOG. The ChR undergoes MOG-dependent tyrosine
phosphorylation and homodimerisation. It promotes insulin and IGF-independent growth of the
oligodendrocyte progenitor cell line CG4. The proposed mode of the ChR activation is by MOG-induced
dimerisation which promotes kinase domain transphosphorylation, by-passing the requirement of
conformation changes known to be important for IGF1R activation. Another ChR, which contains a segment
of the β-chain ectodomain, was produced in an attempt to recapitulate some of these conformational changes,
but proved non-functional.: +44 207 882 6121.
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In order to improve survival of oligodendrocyte progenitors (OPC)
transplanted in the central nervous system for re-myelinating therapy
we explore the approach that involves expressing in them a
transmembrane chimeric receptor (ChR) containing the cytosolic
insulin-like growth factor (IGF) receptor type 1 (IGF1R) kinase and an
ectodomain speciﬁc to a molecule present in the central nervous
system. The idea is that transplanted OPC expressing such ChR will
survive better because they will be able to receive pro-survival signals
at sites of transplantation independently of IGF1R ligand availability.
The IGF1R signalling pathway plays an important role in prevention of
demyelination [1], as well as in regenerative oligodendrogliogenesis
and remyelination [2]. Co-activation of this pathway may be requiredfor optimal signalling via several developmental pathways in
neurogenesis (reviewed in [3]).
We have chosen to target the ChR to myelin oligodendrocyte
glycoprotein (MOG) because this protein is expressed only in the
central nervous system, on the outermost lamellae of myelin and on
the cytoplasmic membrane of mature myelinating oligodendrocytes.
OPC do not express MOG. The ChRwe have generated is a substitution
mutant of the mouse IGF1R in which the ectodomain is replaced with
the single chain variable Fab fragment (scFv) of the MOG-speciﬁc
monoclonal antibody (mAb) Z12 [4]. MOG has the potential to induce
ChR dimerisation, as suggested by dimerised status of MOG isolated
from mammalian brain [5–7]. In addition, the propensity of MOG to
form head-to-tail homodimers is in agreement with the presence of
extensive dimer interface with signiﬁcant shape complementarity in
the extracellular domains of the molecule, as shown by crystal
structure analysis [6]. Homodimer formation by recombinant human
MOG expressed in LN18 cells used in this study for activation of the
ChRs has been shown [8].
The IGF1R consists of two disulphide-linked half-receptors
(Supplementary Fig. S1). Each of these two halves is a disulphide-
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extracellular, and the β-chain, which spans the cytoplasmic mem-
brane and contains the cytosolic kinase domain [9,10]. In the
unliganded IGF1R the autocatalytic activity of the kinase domain is
inhibited in cis [11,12] by conformational constraints imposed by
elements of the receptor outside the kinase domain, including the
extracellular portion of the β-chain [13–15], the transmembrane
segment [16] and the juxtamembrane region [17]. The current model
of IGF1R activation holds that one ligand molecule asymmetrically
binds per IGF1R causing relief of in cis inhibition via incompletely
understood conformational changes [10,18,19].
It is unlikely that these conformational changes can be recapitu-
lated when the ligand binding portion of the IGF1R is replaced with a
heterologous domain, but other authors have been able to construct a
monomeric ChR capable of ligand-dependent activation by replacing
the extracellular and transmembrane portions of the IGF1R with
corresponding portions of the neurotrophin-3 receptor, a receptor
tyrosine kinase activated by ligand-induced dimerisation [20].
Together with other observations [21], this suggests that the
autocatalytic activity of the IGF1R kinase can be regulated by
dimerisation, bypassing thereby the requirement of ligand-dependent
conformational changes. By fusion of the anti-MOG scFv with the
extracellular boundary of the IGF1R transmembrane portion, we
produced the ChR ZigT (Supplementary Fig. S1), which has been
proven capable of MOG-dependent activation. Another construct we
produced, ZigR672 (Supplementary Fig. S1), contains the complete
extracellular portion of the β-chain and forms homodimers. This ChR
has been produced for testing the possibility that these featureswould
provide, respectively, tighter autoinhibition and greater level of
MOG-dependent activation than in ZigT. ZigR672, however, is non-
functional.2. Materials and methods
2.1. Generation of lentivectors expressing ChRs or MOG
Genetic constructs were produced by standard molecular cloning
techniques described in detail in the Supplementary Experimental
Procedures. A DNA fragment encoding the scFv of the mAb Z12
(Genbank accession numbers AJ416331 and AJ416332) was ampliﬁed
from plasmid DNA containing its coding sequence by PCR with
Platinum® Pfx DNA Polymerase (Promega UK, Southampton, UK). In
order to produce the IGF1R portions of ZigT or ZigR672 the ﬁrst strand
cDNA was synthesised from total mouse embryonic RNA using
Moloney Murine Leukaemia Virus reverse transcriptase (Promega)
and ampliﬁed by PCR with primers speciﬁc to the 5′ and 3′ ends of the
target sequences. The PCR products were subcloned, in several steps,
in pCR2.1 together with DNA fragments encoding V5 epitope, the
mouse encephalomyocarditis internal ribosome entry site (IRES) and
enhanced green ﬂuorescent protein (EGFP). The ﬁnal bi-cistronic
inserts consisted of either ZigT or ZigR672, both tagged with V5
(Supplementary Fig. S1), as 5′ cistrons, followed by the IRES and the
EGFP reporter as a 3′ cistron. These were excised with BamHI and
NotI for subcloning between the same sites in the constitutive self-
inactivating lentivector with the spleen focus forming virus promoter
[22].
A DNA fragment encoding mouse MOGwas ampliﬁed from BALB/c
mouse brain mRNA by RT-PCR. Subcloning of the PCR product into the
multiple cloning site of the vector pQCIN (Invitrogen, Paisley, UK)
resulted in the generation of the bi-cistronic construct containing the
gene forMOG, the IRES andneomycin phosphotransferase gene,which
was excised with BamHI and SalI and subcloned in the tetracycline-
inducible lentivector pLox [23] (kindly donated by D. Trono, National
Centre of Competence in Research, Lausanne, Switzerland) between
these restriction sites.Correct sequences of all inserts in the lentivectors were conﬁrmed
by DNA sequence analysis at the Genome Centre, Queen Mary
University of London.
2.2. Generation of cell lines and clones expressing ChRs or MOG
HIV-1-based lentivectors pseudotyped with the vesicular stomati-
tis virus glycoprotein were generated by transient calcium phosphate-
mediated co-transfection [24] of 293 T cells with three plasmids,
the packaging construct ΔR8.2 [25], the vesicular-stomatitis-virus-
glycoprotein-expressing construct pMD.G [26] (kindly donated by I.
Verma, Salk Institute, USA) and a transfer construct, as described [25].
Cells were transduced at a multiplicity of infection in excess of 1. For
doxycycline-inducible MOG expression, pLox with the bi-cistronic
construct encoding MOG and neomycin phosphotransferase was co-
transduced into B104 cells with the lentivector containing a bi-cistronic
construct encoding tetracycline repressor and transactivator [23,27].
Dependent on the reporter gene used, clones were isolated by plating
transduced cells at cloning densities and screening for the EGFP
expression or for the ability to survive in 1 mg/ml of G418 (Invitrogen)
when co-treated with 1 μg/ml of doxycycline (Sigma, Pool, UK).
2.3. Tissue culture
The rat neuroblastoma B104 [28], genetically modiﬁed derivatives
of this cell line and the human glioblastoma cells LN18 expressing or
not recombinant human MOG (LN18hMOG and LN18control, respec-
tively) [8] were cultured in Dulbecco's Modiﬁed Eagle medium
(DMEM; BioWhittaker, Lonza, Verviers, Belgium) supplemented with
10% foetal bovine serum (Invitrogen). In some experiments conﬂuent
monolayers of the stimulatory LN18 cells were ﬁxed with 3.7%
paraformaldehyde (VWR International, Lutterworth, Leicestershire,
UK).
The oligodendrocyte progenitor cell line CG4 [29] (kindly donated
by Huseyin Mehmet, Imperial College London, UK) were cultured in
poly-L-ornithine (Sigma)-coated tissue culture plates. The growth
medium (GM) used consisted of DMEM supplemented with 23 nM
progesterone, 100 μM putrescine, 29 nM sodium selenite, 5 μg/ml
insulin, 5 μg/ml transferrin, 10 ng/ml biotin (all from Sigma), 5 ng/ml
FGF-2, 1 ng/ml PDGFAA (both from BioSource Europe, Nivelles,
Belgium) and 30% B104-conditioned medium. CG4 cells were induced
to differentiate by switching to differentiationmedium (DM)prepared
by supplementing a mixture of DMEM and Ham's F12 (BioWhittaker)
media with 9.5 nM progesterone, 31 μM putrescine, 23.4 nM sodium
selenite, 12.5 μg/ml insulin, 50 μg/ml transferrin, 10 ng/ml biotin,
0.4 μg/ml thyroxine and 3 g/l glucose (all from Sigma). For testing
effects of bovine insulin (Sigma) or rat IGF-IA (PeproTech, London, UK)
on cell growth these proteins were added to DM that was prepared
insulin-free (DMinsulin-free), using cells cultured in DMinsulin-free as
controls.
2.4. Analysis of protein subunit structure and post-translational
modiﬁcations by immunoblotting
Cells were lysed with the buffer consisting of 10 mM Tris pH 7.4,
100 mM NaCl, 50 mM NaF, 0.1% SDS, 1% Triton-X 100 (all from VWR),
1 mMEDTA, 1 mMEGTA, 20 mMNa4P2O7, 2 mMNa3VO4, 0.5% sodium
deoxycholate, 10% glycerol, 1 mM PMSF (all from Sigma) and the
protease inhibitor mixture (Calbiochem, Nottingham, UK) on ice for
20 min, and the lysates were cleared by centrifugation. Some of the
samples were treated with peptide N-glycosidase F (New England
Biolab, Hitchin, Hertfordshire, UK) as recommended by the manufac-
turer at 1–15 U per mg of cellular protein.
Cell lysates weremade up in Laemmli buffer [30]with orwithout 5%
(volume per volume) β-mercaptoethanol (Sigma), and analysed by
polyacrylamide gel electrophoresis using precast NuPAGE®Bis-Tris
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protein contentmeasuredusing theBCA reagent kit (Pierce, Cramlington,
Northumberland, UK). Separated cellular proteins were blotted onto a
Hybond-P PVDF membrane (Amersham, UK) using XCEll II™ Blot
Module (Invitrogen) according to the manufacturer's manual.
Membraneswere blockedovernightwith 2% casein (Fisher Scientiﬁc
UK Ltd, Loughborough, Leicestershire, UK) in PBS containing 2 mM
Na3VO4 and 2 mM NaF before incubation with anti-phosphotyrosine
antibodies, or blocked with 5% non-fat milk for immunoblotting with
other antibodies. Primary and secondary antibodies were diluted in the
buffer used for blocking,whichwas supplementedwith 0.05% Tween20
(VWR). The following phosphotyrosine-speciﬁc antibodieswere used: a
mixtureof themousemAbspY20 (Abcamplc, Cambridge,UK) and4G10
(Millipore Ltd, Watford, UK), 1 μg/ml each (anti-pY), or the rabbit
polyclonal IgG against one of the phosphotyrosines in the activation
loop of the IGF1R and insulin receptor (anti-IR/IGFIR[pY1158]; Bio-
Source) at 1 μg/ml. Other primary antibodies were the V5-epitope-
speciﬁc mAb from Invitrogen (anti-V5), unconjugated or horse radish
peroxidase (HRP)-conjugated, used at 0.1–0.5 μg/ml; and the mouse
mAb Z12 speciﬁc toMOG(kindly donated byGareth Pryce, ICMS, Queen
Mary University of London, UK) used as a hybridoma-conditioned
supernatant at 1:100 dilution. The antibodies used for immunoprecip-
itation of the endogenous IGF1R and insulin receptor were G-5 (IGF1R
α-chain), H-60 (ectodomain of IGF1R β-chain), S-18 (insulin receptor
α-chain) (all from Santa Cruz) and 4B8 (insulin receptor β-chain; Cell
Signaling Technologies). HRP-conjugated secondary antibodies used
were F(ab')2 fragment of rabbit anti-mouse IgG (Zymed Laboratories,
San Francisco, CA) diluted 1:5000, or goat anti-mouse IgG Fab (Santa
Cruz, CA) at 0.4 μg/ml, or sheep anti-rabbit IgG (Serotec, Kidlington,
Oxford, UK) at 1:5000. Streptavidin biotinylated HRP complex (GE
Healthcare UK Ltd., Buckinghamshire, UK) diluted 1:1000 was used for
detection of cellular proteins labelled with biotin. Protein bands were
visualised by exposing membranes developed with the ECL reagent
(Amersham) to chemiluminescence ﬁlm (Hyperﬁlm ECL, Amersham).
HighRangeRainbowmolecularweightMarkers (Amersham)orNovex®
Sharp Prestained Protein Standards (Invitrogen) were used for protein
molecular weight determination.
Cell surface proteins were labelled with Sulfo-NHS-LC-LC-Biotin
(Pierce) as recommended by the manufacturer (at 1 mg per ml per
107 cells). The ChRs were immunoprecipitated from lysates of
biotinylated or unlabeled cells by sequential incubation with anti-
V5 (2.5–5 μg per 1 mg cellular protein) and protein G Sepharose™
Fast Flow beads (GE Healthcare, Uppsala, Sweden; 20 μl per 1 mg
cellular protein), or by incubation with anti-V5 that was covalently
bound to protein G Sepharose™ (2.4 μg per 10 μl) using disuccinimi-
dyl suberate (Pierce) according to the manufacturer's protocol.
Proteins were extracted from the beads in Laemmli buffer with or
without 5% β-mercaptoethanol and analysed by immunoblotting.
3,3'-Dithiobis(sulfosuccinimidylpropionate) (DTSSP, Pierce) was
used for stabilisation of dimerised proteins in ChR-expressing B104
cells stimulated with PFA-ﬁxed monolayers of LN18 cells. DTSSP was
added after 20 h of cell culture, the cells were incubated on ice for 2 h,
lysed and analysed by immunoblotting with anti-V5.
In order to normalise tyrosine phosphorylation to protein content
of the ChRs, proteins immunoprecipitated with anti-V5 were
immunoblotted with anti-pY and then, after stripping at low pH,
with anti-V5. The intensity of bands corresponding to the ChRs was
measured by densitometry using Quantity One® software (Bio-Rad,
Hemel Hempstead, UK). The densitometry value of a band detected
with anti-pY was divided by the densitometry value of a correspond-
ing band detected with anti-V5 (pY/V5).
2.5. ELISA for the ChRs
The ChRs in cell lysates were detected using a modiﬁed ELISA for
anti-MOG antibodies [4]. Microtitre plates (Nunc, Immunoplate,Roskilde, Denmark) were coated with mouse recombinant MOG at
5 μg/ml in 0.05 M carbonate buffer pH 9.6 and blocked with 2% casein
in PBS. Cell lysates were applied in serial two-fold dilutions in PBS
with 2% casein and 0.05% Tween 20 after they had been dialysed
against PBS using dialysis membranes with a cut-off mass of 10 kDa
(BioDesign Inc., NY) and concentrated 10 times using Aquacide
(Calbiochem). MOG-bound ChRs were detected by sequential incu-
bation with anti-V5 at 0.5 μg/ml, HRP-conjugated F(ab′)2 of rabbit
anti-mouse IgG and TMB peroxidase substrate (KPL, Gaithersburg,
MD).
2.6. FACS analysis
Linking a reporter gene to a gene of interest via the IRES is superior
to other methods of gene co-expression [31]. ChR expression in
genetically modiﬁed cells was veriﬁed by measuring the EGFP
reporter expression using FACS. The mAb Z12 was used for detection
of MOG-expression on the cell surface, with F(ab′)2 of donkey anti-
mouse IgG conjugated to phycoerythrin (Jackson ImmunoResearch
Europe Ltd, Newmarket, Suffolk, UK) at 1:100 dilution as a secondary
antibody. FACS Calibur with CellQuest software (Becton Dickinson,
Oxford, UK) was used for analysis. To calculate normalised levels of
ChRs, which were used for comparing expression of ZigT and ZigR672
in genetically modiﬁed cells, the densitometry value of a band
revealed by anti-V5 immunoblotting was divided by the total EGFP
level (mean ﬂuorescence multiplied by the percentage of EGFP-
expressing cells).
2.7. Cell number determination
Cell numbers were determined by measuring cellular ATP content
using the CellTiter-Glo reagent kit (Promega). Relative luminescence
units were converted to μM ATP using ATP (Sigma) standards. Mitotic
cycle duration (tM) was calculated using the formula:
tM =
t
log2
Nt
N0
;
where t—time in culture, N0—initial cell number, Nt—cell number at
the end of culture.
2.8. Real-time quantitative PCR
Total RNA was puriﬁed from cultured cells using RNeasy Plus kit
with genomic DNA elimination columns (Qiagen, Crawley, West
Sussex, UK). The ﬁrst strand cDNA was synthesised using High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA) with random primers from total cellular RNA. The real-time
quantitative PCR was performed at the Genome Centre, Queen Mary
University of London using Taqman® Gene Expression Assay
(Rn00575354_m1; Applied Biosystems) as per the manufacturer's
instructions, with glyceraldehyde 3-phosphate dehydrogenase as the
internal control and the amount of transcript expressed in unmodiﬁed
CG4 cells at time zero as the calibrator. The 2−ΔΔCt method was
applied for calculating relative quantities of transcript [32].
2.9. Statistical analysis
Statistical analysis was performed using Student's t test function of
the Microsoft Excel software. The standard propagation of error
methodwas used in order to carry through the variance of Ct values to
the ﬁnal calculation of relative quantities [32].
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3.1. Subunit composition of the ChRs
Structural analysis of ZigT and ZigR672 performed by immunoblot-
ting with anti-V5 and by immunoprecipitation of surface biotynilated
cellular proteinwith anti-V5 is shown in Fig. 1A and B, respectively. The
apparent molecular weight of reduced ZigT (Fig. 1A and B, ZT, mT;
Fig. 1C) was similar to the molecular weight calculated from its non-
glycosylated sequence (78 kDa). ZigT is expressed predominantly as a
monomer. A small proportion of ZigT molecules forms homodimers, as
evidenced by the presence of a high molecular weight band on a non-
reducing gel (Fig. 1A, ZT, dT). The ChR is not N-glycosylated (Fig. 1C).
The apparent molecular weight of monomeric ZigR672 was higher than
the molecular weight of 108 kDa calculated from a non-glycosylated
sequence (Fig. 1A and B, reduced, ZR, mR). This was reduced by
deglycosylation, approaching the calculatedmolecular weight (Fig. 1C).
On non-reducing gels, a major band of molecular weight in excess of
220 kDa was revealed (Fig. 1A and B, non-reduced, ZR, dR), as well as a
less intense band with the same molecular weight as monomericFig. 1. Biochemical characterisation of the chimeric receptors ZigT and ZigR672. (A) Lysates of
were immunoblotted with the anti-V5 mAb. Horizontal bars show positions of molecular we
and ZigT homodimers (dT). (B) Unmodiﬁed B104 cells and ChR-expressing clones (labelled
the anti-V5 mAb. Cell lysates before IP (“before IP”) were separated (15 μg of cellular pro
detected using streptavidin conjugated HRP complex. Films were exposed for 10 or 30 min. M
with peptide N-glycosidase F at 1 U per mg cellular protein (+) or incubated without the en
were detected by ELISA in concentrated lysates of ChR-transduced B104 cells. Negative cont
receptor common β chain C-terminally tagged with V5 (βc) (unpublished), which is a cell
lysates containing ZigR672 or ZigT in microtitre wells not coated with MOG (not shown) wa
(E) Clones of ZigT- or ZigR672-expressing B104 cell (T5 and R9, respectively), or B104 cell lin
without the IGF1R signalling domain (C) were lysed and immunoprecipitated (IP) with anti-
with anti-V5.ZigR672 (Fig. 1A and B, non-reduced, ZR, mR), suggesting formation of
disulphide-linked homodimers.
ZigR672 contains the furin cleavage site of the IGF1R precursor
where theα- andβ-chains are separated (RRRR at residues 738–741 in
the mouse IGF-I preproreceptor). The ChR, however, is not cleaved at
this site because otherwise biotinylated cleavage products would be
present on reducing gels as bands of 34 kDa and74 kDa, corresponding
to the scFv fusedwith 67 C-terminal amino acids of theα-chain and to
the V5-tagged β-chain, respectively (Supplementary Fig. S1, ZigR672).
In addition, immunoblotting with anti-V5 would detect the V5-tagged
β-chain (74 kDa).
A number of low intensity additional bands speciﬁc to cells
expressing ChRs were detected (Fig. 1). Deglycosylation of ZigT had
no effect on the appearance of these bands (Fig. 1C), suggesting that
they might be a result of N-terminal truncation. After removal of N-
glycosylation, full length ZigR672 and those of the bands that had a
molecular weight higher than 55 kDa were reduced in size, whereas
the size of the bands under 55 kDa was unaffected (Fig. 1C, ZigR672).
Since only the extracellular part of a transmembrane protein
undergoes N-glycosylation, the larger molecular weight additionalunmodiﬁed B104 cells (U), B104ZigR672 clone 9 cells (ZR) and B104ZigT clone 5 cells (ZT)
ight markers, ZigR672 monomers (mR), ZigR672 homodimers (dR), ZigT monomers (mT)
as in A) were cell-surface-biotinylated before lysis and immunoprecipitation (IP) with
tein per lane) as a control of biotinylation efﬁciency. Biotinylated protein bands were
olecular weight standard and band labelling is the same as in A. (C) Cell lysates treated
zyme (−) before being analysed by immunoblotting with anti-V5. (D) ZigR672 and ZigT
rols were an unmodiﬁed cell lysate (U) and a cell lysate containing the mouse cytokine
surface receptor without a MOG-speciﬁc scFv. Signal produced after incubation of cell
s not signiﬁcantly different from the negative controls. Means of duplicates are shown.
es expressing these ChRs (T and R, respectively), or control B104 cells expressing a ChR
V5 or with antibodies against endogenous IGF1R or insulin receptor and immunoblotted
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above the transmembrane portion; the smaller bands may be
truncations below the ectodomain.
We investigated whether or not endogenous and chimeric
receptors formed hybrid molecules. We used a panel of antibodies
for immunoprecipitation of the endogenous receptors from lysates of
ChR-expressing B104 cells. The panel included three antibodies that
did not cross-react with the ChR. These were the antibodies speciﬁc to
IGF1R α-chain, insulin receptor α-chain and insulin receptor β-chain.
The antibody speciﬁc to the IGF1R β-chain ectodomain was used only
with ZigT-containing lysates because it did recognise ZigR672. The
antibodies against the endogenous receptors co-immunoprecipitated
ZigT and ZigR672 (Fig. 1E), suggesting that endogenous α/β-half
receptors can form hybrid molecules with ChRs. Only a small
proportion of ChR molecules, however, less than 1%, appear to be
involved in the formation of such hybrids, as can be approximately
determined by comparing the amount of a ChR in the original cell
lysate with its amount co-immunoprecipitated with an antibody
against IGF1R or insulin receptor (Fig. 1E). Levels of the hybrid
receptors may be limited by availability of endogenous receptors,
which is low in B104 cells because we could not detect endogenous
IGF1R and insulin receptor by immunoblotting with the antibodies
used for immunoprecipitation (not shown).
Contents of ZigT and ZigR672 in lysates of transduced uncloned
B104 cells determined by ELISA (Fig. 1D) roughly correlated with the
results of ChR quantiﬁcation using immunoblotting with anti-V5. The
ability to reveal the presence of ZigR672 in cell lysates using ELISA inFig. 2. Increased autocatalytic activity of ZigT in response to mouse MOG. (A) The clone B104
doxycycline for 4 days (−dox) or with doxycycline for 16 h, 1 day, 2 days, 3 days or 4 days
stained with Z12, including unmodiﬁed B104 cells (−MOG) and B104mMOG_neo-2 cells
B104mMOG_neo-2 cells (M) shown by immunoblotting with Z12 under non-reducing and redu
B104ZigR672-9 were co-cultured with the clone B104mMOG_neo-2 with (+) or without (−) dox
anti-V5 (α-V5) and immunoblotted (IB) with anti-V5 or with anti-pY (α-pY). Tyrosine phos
gel densitometry values (pY/pV5).this format directly shows, in agreement with the results of protein
analysis (Fig. 1A and B), that a MOG-binding domain in the ZigR672
molecule, the Z12 scFv, is covalently linked to the kinase domain.
Therefore, ZigT is expressed on the cell surface as a monomer, with
a low degree of dimerisation, and ZigR672 forms homodimers and is
N-glycosylated at the extracellular part of the IGF1R β-chain. A small
proportion of ChR molecules may be involved in the formation of
heterodimers with endogenous IGF1R and insulin receptor. Both ChRs
can bind MOG.
Assuming that the IRES-driven translation of the EGFP reporter in the
bi-cistronic transcripts encoding ChRs does not depend on the nature
of the 5′ cistron [33] and that the larger ChR ZigR672 is unlikely to be
synthesised at a higher rate than ZigT, we used EGFP-normalised levels
of ChR in transduced cells for comparing their stability (Supplementary
Fig. S2) and have come to the conclusion that ZigR672 degrades at a
slower rate than ZigT.
3.2. Autophosphorylation of ZigT in response to MOG binding
B104mMOG_neo-2 clone express mouse recombinant MOG in a
doxycycline-inducible manner (Fig. 2A). The recombinant protein in
B104 cells forms disulphide-linked homodimers and may be associated
with other cellular proteins via disulphide bonds (Fig. 2B). The clones
B104ZigT-5 and B104ZigR672-9, which constitutively expressed ChRs,
were co-cultured with equal numbers of B104mMOG_neo-2 cells in the
presence of doxycycline or, as a negative control, without doxycycline
(Fig. 2C). Levels of ChR tyrosine phosphorylation normalised to theirmMOG_neo-2 expressing mMOG in a doxycycline-inducible manner was cultured without
and analysed by FACS after staining with the mAb Z12; negative controls were cells not
not treated with doxycycline (−dox-Ab). (B) Formation of MOG homodimers in
cing conditions (C—B104 cells not transduced with MOG). (C) The clones B104ZigT-5 and
ycycline (dox) for 1 or 2 days. ChRs were immunoprecipitated (IP) from cell lysates with
phorylation of ZigT normalised to its protein content is shown on the graph as a ratio of
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level of tyrosine phosphorylation which increased in response to
stimulation with MOG 3-fold compared to unstimulated cells. On the
contrary, ZigR672 displayed neither basal nor MOG-induced tyrosine
phosphorylation because no signal could be detected after immuno-
blotting with anti-pY. Therefore, ZigT was activated by ligation with
MOG, but ZigR672 was not.
The ability of the ChRs to respond to humanMOGwas investigated by
plating clones B104ZigT-5 or B104ZigR672-9 onto live or paraformaldehyde-
ﬁxed monolayers of LN18hMOG or LN18control cells (Fig. 3). Again, ZigT,
but not ZigR672, became tyrosine phosphorylated (Fig. 3A). This could
be visualised even when the immunoprecipitation step was omitted
and PAGE-separated lysates of LN18hMOG-stimulated B104ZigT-5 cells
were immunoblotted with anti-pY (Fig. 3B).
The tyrosine phosphorylation of the activation (A)-loop in the IGF1R
kinase domain precedes phosphorylation of tyrosine residues outside
the A-loop [34]. A-loop activation was involved in ZigT activation, as
shown by immunoblotting with a polyclonal antibody recognising
phosphorylated tyrosine at residue 1163 of the mouse IGF1R (Fig. 3C),
the second tyrosinewithin the A-loop to be phosphorylated in response
to ligand binding [35].
Furthermore, we investigated the possibility of ChR dimerisation in
response to interactionwith homodimers ofMOG. Increase in dimerised
ZigT was observed when the ChR was bound to MOG (Fig. 3D). The
cellular-membrane-impermeable cross-linking reagent DTSSP had
little, if any, effect on stability of the MOG-induced ZigT homodimers.
Therefore, dimerisationmay play a role in ZigT activation. MOG binding
had no effect on the amount of ZigR672 homodimers (Fig. 3D).
The activation of the second messengers AKT and extracellular
signal-regulated kinases p42 and p44 in response to ZigT ligation with
MOG could not be investigated in B104 cells because these molecules
were constitutively active and not subject to dephosphorylation
under serum-free conditions.Fig. 3. Increased autocatalytic activity and dimerisation of ZigT in response to humanMOG. (A
of LN18control (hMOG–) or LN18hMOG (hMOG+) cells for 7 h. Tyrosine phosphorylation of Zig
with anti-V5 exposed for 30 s, ZigR672 and ZigT immunoblots with anti-pY exposed for 15 a
PAGE and αpY immunoblotting. (C) The clone B104ZigT-5 was cultured on pre-establish
monolayers were live (L) or ﬁxed with paraformaldehyde (F). Cell lysates were electrophore
tyrosine residue in ZigT that is the second tyrosine of the A-loop to be phosphorylated upo
B104ZigR672-9 were stimulated with MOG using PFA-ﬁxed monolayers of LN18 cells in the pre
by immunoblotting with anti-V5 (h/d—homodimers, mon—monomers).3.3. Activation of ZigT with MOG is mitogenic in CG4 cells
The OPC line CG4 was chosen for testing functionality of the ChRs
for two reasons. First, when differentiated these cells express MOG,
the ChR ligand. Second, CG4 cells are highly dependent on the
activation of the IGF1R for growth and survival.
CG4 cells were genetically modiﬁed to express ZigT, ZigR672 or
EGFP. In spite of the fact that all lentivectors were used at similar MOI
there was a considerable difference in the EGFP reporter expression
between cells transduced with a mono-cistronic construct with EGFP
only (85.7%, Fig. 4) and cells transduced with bi-cistronic constructs
encoding EGFP as a 3′ cistron (5.2% and 4.3% for ZigR672- and ZigT-
transduced cells, respectively, Fig. 4). This may be explained by lower
efﬁciency of IRES-driven cap-independent translation in comparison
to cap-dependent translation in CG4 cells. However, after switching to
CG4-DM, the percentage of EGFP-expressing cells, as well as the
number of viable cells, in cultures transduced with ZigT continued to
increase and eventually all the cells became EGFP-positive (Fig. 4).
Therefore, it appears that CG4 cells with higher levels of ZigT had a
selective advantage of increased growth. ZigR672 did not confer this
advantage on CG4 cells (Fig. 4).
MOG expression in CG4 cells switched to differentiation-promoting
conditions was a plausible explanation for ZigT activation and
generation of a mitogenic signal. To test this possibility, the population
of ZigT-expressing CG4 cells established as a result of culture in CG4-DM
(Fig. 5A) was re-cultured in CG4-GM and again switched to CG4-DM.
MOG transcript levels in these cells increased and remained at the level
constituting about 1/2000 of the maximum observed in fully differen-
tiated control CG4 cells (Fig. 5D). At theprotein level,MOGexpression in
differentiating CG4 cells was detectable by immunoblotting from day 6,
but levels expressed in Zig-T-expressing cells at all stages of culture
were below detection limit (Fig. 5C).This suggests that the mitogenic
signal driving proliferation of ZigT-expressing CG4 cells under) The clones B104ZigT-5 and B104ZigR672-9 were cultured on pre-establishedmonolayers
T normalised to its protein content is shown on the graph as pY/pV5. The immunoblots
nd 5 min, respectively. (B) The same cell lysates as in (A) were analysed, without IP, by
ed monolayers of LN18control (hMOG -) or LN18hMOG (hMOG +) cells for 7.5 h. The
tically separated and immunoblotted with the antibody speciﬁc to the phosphorylated
n IGF1R activation (α-pIGF1R) or with anti-V5 (α-V5). (D) The clones B104ZigT-5 and
sence or absence of the cross-linking agent DTSSP (XL) before analysis of ChR structure
Fig. 4. ZigT transmits a mitogenic signal in CG4 cells. CG4 cells were transduced with ZigT, ZigR672 or EGFP and cultured for 10 days in GM. Some of the cultures were harvested and
analysed by FACS for EGFP expression. Remaining cultures were switched to DM, cultured for additional 9 days and analysed by FACS. Cells were electronically gated, as shown in
density plots, with numbers representing the percentages of gated cells of the total cell number. EGFP ﬂuorescence of the gated cells is shown as percentage of cells gated inM1 in the
histograms.
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postmitotic, may result from interaction of the ChR with low levels of
MOG expressed at early stages of CG4 cell differentiation and leads to
haltering further cell differentiation.3.4. ZigT confers insulin- and IGF-I-independency on CG4 cells
ZigT-expressingCG4 cells derivedby selection under differentiation-
promoting conditions, as described above, as well as control CG4 cells
were plated in CG4-GMor in CG4-DM(Fig. 6). Immediately after plating
the numbers of ZigT-expressing and control cell were equivalent,
respectively, to 0.79±0.03 (mean±SD; n=4) and 0.61±0.02
(mean±SD; n=3) μM ATP (Fig. 6A, 0 days). After 2 days in CG4-GM
cell numbers increased, respectively, to 5.33±0.12 and 5.71±0.29 μM
ATP (mean±SD, n=3; Fig. 6A, GM), which, assuming there was no cell
death, corresponded to the doubling time of 15.4 and 16.8 h,
respectively (8.3% shorter cell cycle duration in the presence of ZigT).Before undergoing mitotic cycle arrest after switching to differen-
tiation-promoting conditions control CG4 cells continue to proliferate
for 2 days if cultured in the presence of insulin (Fig. 6B) or IGF-IA
(Fig. 6C) at concentrations sufﬁcient to activate at least their respective
receptors which is in agreement with an observation of other authors
[36]. Without insulin or IGF-I stimulation (2 days in CG4-DMinsulin-free),
the number of control cells did not increase (0.72±0.16; mean±SD;
n=4) (Fig. 6A, DMinsulin-free), but the number of ZigT-expressing cells
increased 4.23 times to become 2.57±0.01 μMATP (mean±SD; n=3)
(Fig. 6A, DMinsulin-free), corresponding to the doubling time of 23.1 h.
Supplementation of DMinsulin-free with increasing concentrations of
IGF-IA or insulin did not stimulate the growth of ChR-expressing CG4
cells. Thus, ZigT can functionally substitute IGF1R.
4. Discussion
The catalytic activity of the kinase domain in the IGF1R and the
closely related insulin receptor largely depends on the conformation
Fig. 5. MOG expression in differentiating CG4 cells. (A) EGFP ﬂuorescence in CG4 cells transduced with ZigT gene and cultured in DM for 30 days shown as the percentage of
M1-gated cells of the viable cell number/the mean ﬂuorescence intensity of the M1-gated cells. The percentage of control cells gated in M1 and their mean ﬂuorescence were 0.46
and 11.7, respectively. (B) The ZigT-expressing cells and unmodiﬁed CG4 cells were plated in GM and switched to DM after 2 days. Microphotographs of these cultures on d 9 in
white and UV light were taken using Zeiss IM35 microscope and Cannon DS126071 DC 8.1v camera. (C) ZigT and MOG expression in unmodiﬁed and the ZigT-expressing CG4 cells
transduced and DM-selected CG4 cells was analysed on indicated days after switching to DM by immunoblotting. MOG expression in ZigT-transduced CG4 cells could only be
detected by quantitative PCR. (D) Levels of MOG transcripts in the cells were determined by real-time quantitative PCR immediately before switching to GM (d 0) and at indicated
time points thereafter. Means of triplicates are shown with SD.
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encompasses tyrosine residues at positions 1163, 1167 and 1168.
Unphosphorylated Y1167, the ﬁrst tyrosine to be phosphorylated in
response to ligand binding, binds to the active site of the same kinase
domain interfering in cis with binding of the ATP molecule [11,12].
The autoinhibitory conformation of the kinase domain in unliganded
IGF1R is maintained via a mechanism that largely depends on the
integrity of the β-chain [13–17]. Ligand binding to the receptor causes
shift in A-loop conformation [37], facilitating ATP binding and proper
positioning of the A-loop tyrosines against the active site of the
second kinase domain for phosphorylation in trans [35,38].Fig. 6. ZigT can functionally replace the IGF1R. (A) ZigT-expressing (ZigT) and EGFP-expressin
CG4-DMinsulin-free (DMinsulin-free) and cultured for 2 days. (*)pb10−7 compared to the initial
with increasing concentrations of insulin and cultured for 2 days. (*) p‹10-3 compared to ins
insulin and increasing concentrations of IGF-IA cultured for 2 days. (*) p‹0.014, (**) pb2×1Ligand-dependent functionality of ZigT, shown by ChR autopho-
sphorylation in response to MOG and by generation of a mitogenic
signal in differentiating OPC expressing MOG, suggests that IGF1R
kinase domains can be activated via an alternative mechanism,
which does not involve rearrangement of receptor molecular
domains. In order to elucidate a potential mode of ZigT activation
we compared this ChR with other published monomeric IGF1R
mutants (Supplementary Table 1). Some of them are constitutively
active. However, in spite of the absence of inhibition in cis, which is
a likely status of these constructs because they have deletions in the
β-chain ectodomain, the monomeric mutants ErbB2V/IGF-1R [39],g control CG4 cells were plated (104 cells/well of a 96-well plate) in CG4-GM (GM) or in
cell number (d 0). (B) Cells plated as in (A) in CG4-DMinsulin-free supplemented or not
ulin-free conditions. (C) Cells plated as in (A) in CG4-DMif supplemented with 0.86 nM
0-4, (***) pb10−6 compared to the lowest IGF-IA concentration.
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autocatalytic activity and can be activated by dimerising ligands. In
addition, A-loop tyrosine phosphorylation in soluble IGF1R cytoplasmic
portions can be induced by dimerisation [21]. In support of the idea
that dimerisation-induced kinase domain trans-phosphorylation is a
potential mechanism of ZigT activation we have conﬁrmed here that
MOG can form homodimers. We also show increase in the proportion
of dimerised ZigT molecules in response to MOG ligation. ZigT
homodimers are dependent on the formation of disulphide bonds and
pre-exist before stimulation with MOG, suggesting that the effect of
MOG may be to stabilise these homodimers. Therefore, it is possible to
replace functionally the IGF1R with a monomeric ChR containing the
IGF1R kinase domain in which ligand-dependent increase in autocat-
alytic activity is achieved by dimerisation, bypassing the complex
and incompletely understood interactions between IGF1R molecular
domains required for kinase domain activation.
Our attempt to recapitulate some of these interactions in ZigR672
was unsuccessful. The ChRwas expected to have increased propensity
to transphosphorylate the IGF1R kinase domains because of consti-
tutive dimerisation presumably mediated by disulphide bonds
between the C-terminal cysteines in the remainder of the α-chain
(Supplementary Fig. S1), amino acid residues that in the IGF1R are
involved in the formation of disulphide bonds between the two α-
chains (C700, 701 and 703). This, however, appears to be overridden by
conformational constraints of unknown nature that prevent MOG-
dependent functionality of the ChR.
Both ChRs form heteroreceptors with endogenous IGF1R and
insulin receptor α/β heterodimers. There is no obvious reason why
hybrids of ZigT and the endogenous receptors cannot be activated by
MOG, whereas IGFs and insulin are known to be unable to bind to α/β
half receptors with high afﬁnity. The proportion of ChR molecules
involved in the formation of heteroreceptors is small, perhaps,
because of low expression levels of the endogenous receptors in
B104 cells. ZigT supported CG4 cells growth under conditions when
IGFs or insulin was absent (Fig. 6). Because of low expression of
endogenous IGF1R and insulin receptor in B104 cells it was impossible
to investigate whether the endogenous receptors are phosphorylated
in response to MOG in ZigT-expressing cells. Neither IGF-IA nor
insulin at the concentration of 100 nM induced tyrosine phosphor-
ylation of ZigT (not shown). Collectively, this experimental evidence
supports the notion that ZigT can function independently of
endogenous IGF1R and insulin receptor, but hybrid molecules might
contribute to MOG-induced ChR activation.
In primary oligodendrocyte progenitors, IGF1R activation has no
mitogenic action in the absence of FGF-2, but can enhance cell
proliferation in response to this growth factor [40,41]. Furthermore,
insulin, a component of CG4-DM, does not prevent mitotic cycle arrest
in differentiating unmodiﬁed CG4 cells. Therefore, the continuous
slow proliferation of ZigT-expressing CG4 cells in the absence of
added growth factors we describe here may be a peculiarity of
intracellular signalling induced by ZigT interactionwith endogenously
produced MOG (Fig.5D). Indeed, intracellular activation of the IGF1R
has been shown to elicit a cellular response that is different from the
response induced by ligation of the receptor expressed on the cell
surface [42]. In addition, CG4 cells may generally have a decreased
threshold to activation with factors that are not mitogenic for
primary OPC when applied on their own, but have the ability to
enhance effects of mitogenic factors, as suggested, for example, by the
ability of CG4 cells over-expressing αvβ3 integrin to proliferate in
response to stimulation with ﬁbronectin, an αvβ3 integrin ligand, in
the absence of added growth factors [43].
Expression of ZigT in transplanted OPC may improve the outcome
of transplantation because when activated by endogenous MOG,
expressed at an early stage of OPC differentiation, the ChRwill prevent
mitotic cycle arrest, allowing for increased expansion and, perhaps,
dissemination of transplanted cells in the central nervous system.Application for remyelinating therapy requires inducible expression
of ZigT because in order to facilitate OPC differentiation into
myelinating oligodendrocytes the expression of the ChR has to be
switched off. This work is now in progress. Furthermore, biological
safety of the ChR can be improved by selective deletion of segments
shown to play a role in oncogenic transformation mediated by the
IGF1R because these segments do not signiﬁcantly overlap with
regions mediating anti-apoptotic effects [44–47]. In addition, in an
attempt to understand causes of differentiation blockade induced by
activation of ZigT with endogenous MOG, which may provide insights
into mechanisms of oligodendroglial differentiation, we are char-
acterising the phenotype of these partially differentiated cells.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.04.006.
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